Anshul Mangal

Opinion author

Anshul Mangal is a biotech entrepreneur, experienced executive, board member, philanthropist and attorney. He is the president of Project Farma, Precision for Medicine’s Manufacturing Solutions. He is also a board member at the Alliance for Regenerative Medicines, Alliance for mRNA Medicines and IQHQ.

Opinion

How the FDA Is Accelerating Cell and Gene Therapy’s Next Chapter

Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.

November 14, 2025

6 min read

Anshul Mangal

Pictured: Supreme Court building/Courtesy Adobe St

Opinion

The End of Chevron Deference Could Open a New Era of Biotech

While the full impact of the Supreme Court decision remains unknown, the new regulatory landscape could be a net positive for drug developers.

November 20, 2024

6 min read

Anshul Mangal

Biopharma collage of scientist, deals, and pills

Opinion

When Should Biopharma Companies Buy, Partner or Develop Innovative Assets?

Here’s how to assess whether to develop a new therapy by building a proprietary platform, acquiring another company or asset or partnering with an established entity.

April 24, 2024

6 min read

Anshul Mangal